Opus Genetics

Academy of Managed Care Pharmacy is a national professional association of pharmacists and other health care practitioners that promote the development and application of pharmaceutical care, in order to ensure appropriate health care outcomes for all individuals. The academy, located in Alexandria, Va., has more than 4,800 members who provide comprehensive coverage nationally to over 200 million Americans served by managed care. Academy of Managed Care Pharmacy was founded in 1989 and is a charter member of the Council on Credentialing in Pharmacy. It is funded primarily through membership dues, grants from pharmaceutical industry manufacturers and the Foundation for Managed Care Pharmacy, and income from conferences and educational programs.

Adeona Pharmaceuticals is a development-stage, specialty pharmaceutical company that develops orally active, proprietary, late-stage drug candidates for the treatment of autoimmune diseases and central nervous system diseases. It focuses on the development of oral therapies for the treatment of rheumatoid arthritis, multiple sclerosis and age-related macular degeneration. The company manufactures Trimesta, which is as an oral, immunomodulatory and anti-inflammatory agent for the North American market. Adeona Pharmaceuticals also develops a series of rationally designed and small-molecule inhibitors. It additionally offers oral flupirtine that is a centrally active oral therapy for the treatment of fibromyalgia syndrome. The company has operations throughout Michigan.

GlycoMimetics develops novel small molecule therapeutics based upon the roles that carbohydrates play in biological processes. The company believes that carbohydrate mimics, or glycomimetic compounds, represent a new class of drugs. It has identified some compounds with potential therapeutic utility. One class has potential in the treatment of infectious diseases with a novel mechanism of action; the second is a class of anti-inflammatory compounds that have been shown to reduce key measures of inflammation. One of GMI s lead opportunities is to treat or prevent infections caused by Pseudomonas aeruginosa. Its objective in this program is to develop a drug that would be used in conjunction with antibiotics against chronic infections that have failed to respond to antibiotic treatment. The company also has compounds that inhibit selectin binding. Its initial focus in this program is to develop a product to treat acute exacerbations of asthma and chronic obstructive pulmonary disease. GlycoMimetics is headquartered in Gaithersburg, Md.